Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinyouli for Neutropenia Prevention in Elderly SCLC
NCT03776604Unknown
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegylated granulocyte colony-stimulating factor in neutropenia, sponsored by CSPC Baike Biopharmaceutical. Primary endpoints: The incidence of grade III/IV neutropenia in the first cycle of PEG-rhG-CSF at Cycle 1 and The incidence of grade III/IV neutropenia in the second cycle of PEG-rhG-CSF at Cycle 2. Status: unknown.
02
Drugs
pegylated granulocyte colony-stimulating factor
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03776604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776604.